Latest Breaking News On - Wakefulness test - Page 3 : comparemela.com

Alkermes Sleeping Disorder Studies Data Look Excellent, Analyst Says

On Tuesday, Alkermes plc ALKS revealed topline results from the narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) cohorts of a phase 1b,…

Wakefulness testReaking news

The Role of Orexin Receptor 2 Agonists in Sleep and Narcolepsy Type 1

Elena Koundourakis, the head of the Orexin Franchise Development and Portfolio Strategy at Takeda, shares her thoughts on the recent positive topline results from a phase 2 trial evaluating TAK-861, an oral orexin receptor 2 agonist, in patients with narcolepsy type 1.

Elena koundourakisOrexin franchise developmentPsychiatric timesPortfolio strategyWakefulness testSleep disordersOrexin receptor 2 agonistNarcolepsy type 1

Takeda s Oral Orexin Agonist to Enter Phase 3 Narcolepsy Trials

Takeda announced results from a phase 2b trial evaluating TAK-861, an oral orexin receptor 2 agonist, in patients with narcolepsy type 1.

Sarah sheikh mscWakefulness testSarah sheikh

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024
financialpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialpost.com Daily Mail and Mail on Sunday newspapers.

United statesNew yorkJoe oconnorYuko yoneyamaChris stammBarbara shecterGabriel friedmanExchange commissionUpcoming scientific congressBell canadaInternational mediaTakeda pharmaceutical company limitedNational postBusiness wireRapidly initiateFirst global phase

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK861 an Oral Orexin Agonist in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Takeda TSE4502NYSETAK today announced positive topline results from a randomized doubleblind placebocontrolled multiple dose Phase 2b trial evaluating TAK861 an oral orexin receptor 2 OX2R agonist in patients with narcolepsy type 1.

United statesYuko yoneyamaTakeda pharmaceutical company limitedExchange commissionUpcoming scientific congressKey secondary endpoints were metNarcolepsy typeGenerally safeResults willUpcoming scientificWakefulness testAnnual reportMedia contactTakeda tak861 orexin receptor 2 ox2r narcolepsy type 1 nct05687903 nct05687916 nt1 nt2 maintenance of wakefulness test epworth sleepiness scale weekly cataplexy rate sarah sheikh gastrointestinal inflammation rare diseases plasmaderived therapies oncology neuroscience vaccines